{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:57:38Z","timestamp":1781996258868,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ANRS|MIE"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combined antiretroviral therapy (ART) management guided by the cell-associated HIV-DNA genotypic resistance test (GRT) is not standardized, and its interpretation may be difficult in the presence of APOBEC3-induced mutations at drug resistance-associated positions (APOMut). Our objective was to evaluate the virologic outcome of people living with HIV (PLWH) with HIV-DNA provirus carrying APOMuts when switched to or receiving an ART regimen that would theoretically be significantly impacted by those APOMut (potential APOMut-impacted treatment, PAIT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PLWH under PAIT and with a cell-associated HIV-DNA GRT containing APOMut between April 2010 and December 2023 were included. Treatment failure was defined as two consecutive plasma viral load values &amp;gt;50\u2005c\/mL at least 1\u2005month apart after the switch to PAIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 38 PLWH who received 42 distinct PAIT lines. At the time of PAIT introduction, all individuals except one were virally suppressed. Virologic failure occurred in four PLWH; all of these cases were related to either poor ART adherence or ART interruption. Two of them switch to another ART: one for galenic adaptation, and the other due to the emergence of the N155H resistance mutation in integrase. For this individual, virologic suppression was obtained with a PI-containing ART. The two others resumed virologic suppression without any ART switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the presence of APOMut in cell-associated HIV-DNA GRTs, virologic suppression was maintained in PLWH switching to PAIT. Virologic failures were unrelated to the presence of APOMut. These results suggest that APOMuts should not be considered in the management of ART.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf353","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:25:33Z","timestamp":1757330733000},"page":"3133-3138","source":"Crossref","is-referenced-by-count":2,"title":["How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?"],"prefix":"10.1093","volume":"80","author":[{"given":"Marie","family":"Gilbert","sequence":"first","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine Marie","family":"Ferr\u00e9","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romane","family":"Guilbaud","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Digumber","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]},{"name":"Service de Pharmacologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-4941","authenticated-orcid":false,"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2402-643X","authenticated-orcid":false,"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]},{"name":"ANRS Maladies Infectieuses \u00c9mergentes, Inserm , F-75013 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMRS1137 IAME , F-75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2025110817253714100_dkaf353-B1"},{"key":"2025110817253714100_dkaf353-B2","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"2025110817253714100_dkaf353-B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jviromet.2017.10.016","article-title":"Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy","volume":"251","author":"Allavena","year":"2018","journal-title":"J Virol Methods"},{"key":"2025110817253714100_dkaf353-B4","doi-asserted-by":"publisher","first-page":"ciaf161","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing HIV proviral DNA to assess for the presence of HIV drug resistance","volume":"3","author":"Wensing","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025110817253714100_dkaf353-B5","doi-asserted-by":"publisher","first-page":"105551","DOI":"10.1016\/j.jcv.2023.105551","article-title":"Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals","volume":"168","author":"Armenia","year":"2023","journal-title":"J Clin Virol"},{"key":"2025110817253714100_dkaf353-B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.chembiol.2017.10.007","article-title":"APOBEC enzymes as targets for virus and cancer therapy","volume":"25","author":"Olson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2025110817253714100_dkaf353-B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cmi.2015.10.004","article-title":"Contribution of APOBEC3G\/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants","volume":"22","author":"Noguera-Julian","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2025110817253714100_dkaf353-B8","doi-asserted-by":"publisher","first-page":"e1002550","DOI":"10.1371\/journal.pgen.1002550","article-title":"APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete \u201call or nothing\u201d phenomenon","volume":"8","author":"Armitage","year":"2012","journal-title":"PLoS Genet"},{"key":"2025110817253714100_dkaf353-B9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(03)00423-9","article-title":"DNA deamination mediates innate immunity to retroviral infection","volume":"113","author":"Harris","year":"2003","journal-title":"Cell"},{"key":"2025110817253714100_dkaf353-B10","doi-asserted-by":"publisher","first-page":"e0005222","DOI":"10.1128\/cmr.00052-22","article-title":"Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells","volume":"35","author":"Chu","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2025110817253714100_dkaf353-B11","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1097\/QAD.0b013e3283560703","article-title":"E138k and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure","volume":"26","author":"Fourati","year":"2012","journal-title":"AIDS"},{"key":"2025110817253714100_dkaf353-B12","doi-asserted-by":"publisher","first-page":"106492","DOI":"10.1016\/j.ijantimicag.2021.106492","article-title":"Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV","volume":"59","author":"Armenia","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025110817253714100_dkaf353-B13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G \u2013&gt; A hypermutation","volume":"16","author":"Rose","year":"2000","journal-title":"Bioinformatics"},{"key":"2025110817253714100_dkaf353-B14","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/jmv.25474","article-title":"Routine drug resistance testing in proviral HIV-1 DNA: prevalence of stop codons and hypermutation, and associated factors","volume":"91","author":"Alidjinou","year":"2019","journal-title":"J Med Virol"},{"key":"2025110817253714100_dkaf353-B15","doi-asserted-by":"publisher","author":"Engel","DOI":"10.1002\/jia2.26370"},{"key":"2025110817253714100_dkaf353-B16","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/jac\/dkad344","article-title":"Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir\u200a+\u200alamivudine simplification in the ANRS 167 LAMIDOL trial","volume":"78","author":"Mazouz","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025110817253714100_dkaf353-B17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/jac\/dkae007","article-title":"Use of genotypic HIV DNA testing: a DELPHI-type consensus","volume":"79","author":"Andre-Garnier","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3133\/64420830\/dkaf353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3133\/64420830\/dkaf353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:25:43Z","timestamp":1762640743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/11\/3133\/8267120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf353","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,29]]}}}